Get the Stockscreener App
4.62
3.12%
0.14
After Hours:
4.39
-0.23
-4.98%
Verrica Pharmaceuticals Inc stock is traded at $4.62, with a volume of 65,313.
It is up +3.12% in the last 24 hours and down -17.06% over the past month.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
See More
Previous Close:
$4.48
Open:
$4.48
24h Volume:
65,313
Relative Volume:
0.42
Market Cap:
$79.37M
Revenue:
$35.58M
Net Income/Loss:
$-17.89M
P/E Ratio:
-6.7712
EPS:
-0.6823
Net Cash Flow:
$-17.74M
1W Performance:
-19.09%
1M Performance:
-17.06%
6M Performance:
+12.96%
1Y Performance:
-3.08%
1-Day Range:
$4.47
$4.76
1-Week Range:
$4.245
$5.96
52-Week Range:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Name
Verrica Pharmaceuticals Inc
Sector
Industry
Phone
484-453-3300
Address
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
4.62 | 76.96M | 35.58M | -17.89M | -17.74M | -0.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-25-23 | Upgrade | Needham | Hold → Buy |
| Mar-22-23 | Initiated | Jefferies | Buy |
| Feb-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-25-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-20 | Initiated | Northland Capital | Outperform |
| Mar-24-20 | Initiated | Needham | Buy |
| Feb-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
Nasdaq Moves: How does Verrica Pharmaceuticals Inc perform in inflationary periodsDollar Strength & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Verrica Pharmaceuticals reports 2025 results and YCANTH sales growth - MSN
Dip Buying: Is Verrica Pharmaceuticals Inc a turnaround story2026 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm - Business Wire
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - Bluefield Daily Telegraph
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - The Joplin Globe
Verrica Pharmaceuticals appoints Chris Chapman as chief commercial officer - MSN
Verrica Pharmaceuticals upgraded to buy from hold at Brookline - MSN
Verrica Pharmaceuticals schedules conference call to discuss 2025 results - MSN
Verrica Pharmaceuticals Reports 2025 Results and YCANTH Sales Growth - MyChesCo
Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability - Sahm
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail
Verrica Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Verrica Pharmaceuticals Gains CHMP Support for YCANTH® Marketing Application in Europe - MSN
Verrica Pharmaceuticals Achieves 130% YCANTH Revenue Growth in 2025, Expands Global Pipeline, and Extends Cash Runway into 2027 - Minichart
Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlig - GuruFocus
Verrica Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Verrica Pharmaceuticals Q4 2025 sees revenue surge By Investing.com - Investing.com South Africa
Earnings call transcript: Verrica Pharmaceuticals Q4 2025 sees revenue surge - Investing.com Canada
YCANTH (VP-102): FDA-Approved Treatment for Molluscum Contagiosum and Dermatology Pipeline Overview | 2025 10-K Highlights - Minichart
VRCA: Revenue surged 368% in 2025, with strong YCANTH growth, cost cuts, and pipeline advances - TradingView
Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Quarterly Earnings Results - MarketBeat
Verrica (VRCA) Achieves Strong Financial Milestones in 2025 - GuruFocus
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Verrica Pharmaceuticals 2025 10-K: $35.6M Revenue, $(1.68) EPS - TradingView
[10-K] Verrica Pharmaceuticals Inc. Files Annual Report | VRCA SEC FilingForm 10-K - Stock Titan
Verrica Pharmaceuticals Q4 revenue jumps on stronger YCANTH demand - TradingView
VRCA: Revenue up 370% in 2025, net loss narrowed, debt repaid, and YCANTH sales nearly doubled - TradingView
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Zacks Research to Hold - MarketBeat
Verrica Pharmaceuticals Schedules Conference Call to Discuss 2025 Results - MyChesCo
Earnings Outlook For Verrica Pharmaceuticals - Benzinga
Verrica Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
FRAUD AND MANIPULATION—E.D. Pa.:... - VitalLaw.com
Verrica Secures $10 Million Milestone as YCANTH Wins Approval in Japan - MSN
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISI - GuruFocus
West Chester-based Verrica partner launches YCANTH in Japan - MSN
Is Verrica Pharmaceuticals Inc stock good for income investorsPortfolio Gains Summary & Safe Capital Growth Tips - baoquankhu1.vn
Aug Highlights: Can Verrica Pharmaceuticals Inc continue delivering strong returnsJuly 2025 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Verrica Pharmaceuticals Inc expected to post a loss of 79 cents a shareEarnings Preview - TradingView
Verrica Investors Gain Class Status Over Delayed FDA Approval - Bloomberg Law News
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - Sahm
Pharma Co. Investors Secure Class Cert. Over FDA Obstacles - Law360
Verrica Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Verrica Pharmaceuticals at TD Cowen Conference: Strategic Insights - Investing.com
VRCA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VRCA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Common Warts Market: Expanding Revenue Landscape to 2034 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Common Warts Market: Expanding Revenue Landscape To 2034 Delveinsight Nielsen Biosciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Mena FN
Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):